Colorado Serum Brucella Abortus RB-51 is for use in
healthy female cattle 4 to 12 months of age as an aid in the prevention of
infection and abortion caused by Brucella abortus.
For use by or under the supervision of a veterinarian. Distribution in the
United States shall be limited to authorized recipients designated by proper
state officials under such additional conditions as these authorities may
require.
Rehydrate with accompanying vial of sterile diluent.
Diluent is a buffered solution specifically prepared for use with this vaccine.
Shake well after rehydration. Use entire contents when first opened. Do not
vaccinate within 3 weeks before slaughter.
Do not administer to pregnant cows.
Inject
2ml subcutaneously.
Anaphylactoid reaction may occur following
administration of products of this nature. If noted, administer adrenalin or
equivalent.
In the event of accidental human exposure, consult a physician. WARNING – this
organism is Rifampin and Penicillin resistant.
Burn, autoclave, or chemically disinfect container and all unused contents.
Store at 2-8°C. DO NOT FREEZE.
Contains a mutant rough form of the parent organism. This product does not appear to cause undulant fever in people, but the lack of sufficient data precludes this definitively.- In vivo studies in test animals,
demonstrate growth of the organism at injection site and regional lymph
nodes.
- Contact your physician. The above
product (Brucella Abortus) contains live bacterial organisms. Local
swelling at the injection site is possible from the bacterin or from
contaminated equipment. The organism is resistant to Penicillin and
Rifampin. CDC recommends the physician prescribe 100mg doxycycline BID x
21days for exposure to this organism. (See the end of page for reference
material regarding Brucella abortus.)
The following is reference material regarding exposure to
Brucella. The Center for Disease Control also has these articles on the
website:
(Excerpt from paper: Gerhardt GG, Roop RM, Bagchi T, Boyle
S, Buhrman D, and Sriranganathan N. Biological properties of RB51; a stable
rough strain of Brucella abortus. Veterinary Microbiology, 28 (1991), 171-188.
States: RB-51 strain was susceptible to: crythromycin, ampicillin,
chloramphenicol, gentamycin, kanamycin, neomycin, oxytetracycline,
carbenicillin, cephalothin, streptomycin, nitrofurantoin, tetracycline and
trimethoprim/sulfamethoxazole. Resistant to: triple sulfa, penicillin,
furazolidone, rifampin.
Excerpt from paper: J. Vet Pharmacol. Therap. 28, 185-201,
2005, entitled: Veterinary pharmacovigilance. Part 4. Adverse reactions in
humans to veterinary medicinal products. (The 26 subjects referenced below
contacted Colorado Serum Company initially, during the first year of RB-51
usage, and we forwarded on to CDC for their surveillance study): A recent study
reported on humans exposed to Brucella abortus strain RB-51 via vaccination.
The Centers for Disease Control (CDC) in the US conducted passive surveillance
for accidental injection with exposure to the vaccine and received reports from
26 affected individuals (via Colorado Serum Company). Of these, 21 subjects had
suffered needle stick injuries, while four had received conjunctival spray
exposure and one an exposure to an open wound. There were no clear cases of
brucellosis in these individuals, suggesting that this strain might have low
pathogenicity to humans but at present, there is insufficient data to determine
if the strain can cause systemic brucellosis in humans.” (Ashford et al., 2004)